Jay Olson
Stock Analyst at Oppenheimer
(3.85)
# 720
Out of 4,761 analysts
236
Total ratings
42.11%
Success rate
12.27%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Outperform | $58 → $62 | $15.56 | +298.46% | 13 | Feb 7, 2025 | |
| EXEL Exelixis | Downgrades: Perform | $41 → $33 | $36.85 | -10.45% | 6 | Jan 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $60 → $40 | $12.17 | +228.68% | 9 | Jan 13, 2025 | |
| QTTB Q32 Bio | Maintains: Outperform | $80 → $20 | $2.57 | +678.21% | 2 | Dec 11, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $30 | $4.12 | +628.16% | 1 | Dec 6, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $17 → $20 | $4.01 | +399.38% | 2 | Dec 4, 2024 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $33 → $15 | $2.24 | +569.64% | 2 | Nov 18, 2024 | |
| BIIB Biogen | Maintains: Outperform | $270 → $255 | $140.64 | +81.31% | 25 | Oct 31, 2024 | |
| SAGE Sage Therapeutics | Maintains: Perform | $9 → $8 | $7.31 | +9.44% | 8 | Oct 30, 2024 | |
| INCY Incyte | Maintains: Outperform | $81 → $82 | $72.11 | +13.72% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $60 | $41.34 | +45.14% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $336.23 | +4.10% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $4.51 | +121.73% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $34.07 | +305.05% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.27 | +252.42% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $11.66 | +311.66% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $303.01 | +25.41% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $120.69 | +81.46% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $1.92 | +525.00% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $4.22 | +326.54% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $1.77 | +464.97% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $47.91 | +98.29% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $19 | $19.95 | -4.76% | 14 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.98 | +738.93% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $32.32 | +132.05% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.58 | +1,443.21% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 | $5.96 | +1,242.28% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $1.76 | +1,320.45% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $11.06 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $1.48 | +3,278.38% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $8.03 | +161.52% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $68 | $20.73 | +228.03% | 3 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $5 → $3 | $0.93 | +221.82% | 5 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.30 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.68 | +375.11% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.30 | - | 3 | Jul 11, 2017 |
Prothena Corporation
Feb 7, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $15.56
Upside: +298.46%
Exelixis
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $36.85
Upside: -10.45%
Intellia Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $12.17
Upside: +228.68%
Q32 Bio
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $2.57
Upside: +678.21%
Sagimet Biosciences
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $4.12
Upside: +628.16%
Terns Pharmaceuticals
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $4.01
Upside: +399.38%
Inovio Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $33 → $15
Current: $2.24
Upside: +569.64%
Biogen
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $140.64
Upside: +81.31%
Sage Therapeutics
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $7.31
Upside: +9.44%
Incyte
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $72.11
Upside: +13.72%
Oct 28, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $41.34
Upside: +45.14%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $336.23
Upside: +4.10%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $4.51
Upside: +121.73%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $34.07
Upside: +305.05%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $2.27
Upside: +252.42%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $11.66
Upside: +311.66%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $303.01
Upside: +25.41%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $120.69
Upside: +81.46%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $1.92
Upside: +525.00%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $4.22
Upside: +326.54%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $1.77
Upside: +464.97%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $47.91
Upside: +98.29%
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $19.95
Upside: -4.76%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $2.98
Upside: +738.93%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $32.32
Upside: +132.05%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.58
Upside: +1,443.21%
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $5.96
Upside: +1,242.28%
Mar 5, 2024
Reiterates: Outperform
Price Target: $25
Current: $1.76
Upside: +1,320.45%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $11.06
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $1.48
Upside: +3,278.38%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $8.03
Upside: +161.52%
Jun 6, 2023
Maintains: Outperform
Price Target: $70 → $68
Current: $20.73
Upside: +228.03%
Mar 6, 2023
Maintains: Perform
Price Target: $5 → $3
Current: $0.93
Upside: +221.82%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.30
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.68
Upside: +375.11%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.30
Upside: -